Seelos Therapeutics Teams Up with Aptar Pharma for Drug Delivery Device

April 7, 2021

New York-based Seelos Therapeutics has partnered with Aptar Pharma of Crystal Lake, Ill., for access to its Bidose (BDS) Liquid System, a device that Seelos plans to use for delivery of its intranasal ketamine candidate.

The partnership covers Seelos' use of Aptar's BDS Liquid System with its ketamine product, SLS-002, which is currently in development for the treatment of acute suicidal ideation and behavior in patients with Major Depressive Disorder.

The intranasal delivery system can be used without priming or shaking, making it useful in crisis situations. The device has already been cleared by the FDA and the European Medicines Agency for the delivery of other therapeutics, and the partnership agreement leaves the door open for Seelos to use the device for future indications.

View today's stories